Antibody ID	ANI0AFLXT
Antibody Name	Anti-FOLR1 mAb
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	Folate receptor alpha (FOLR1)					Antigen Info

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100.00%	High FOLR1 expression (FOLR1+++; IHC H-score=300)
Method Description	IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FR expression and compared to IMGN853.
In Vivo Model	KB CDX model
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100.00%	Moderate FOLR1 expression (FOLR1++; IHC H-score=140)
Method Description	IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FR expression and compared to IMGN853.
In Vivo Model	IGROV-1 CDX model
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100.00%	Moderate FOLR1 expression (FOLR1++; IHC H-score=100)
Method Description	IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FR expression and compared to IMGN853.
In Vivo Model	Ishikawa CDX model
In Vitro Model	Endometrial adenocarcinoma	Ishikawa cells		CVCL_2529
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100.00%	Low FOLR1 expression (FOLR1+; IHC H-score=30)
Method Description	IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FR expression and compared to IMGN853.
In Vivo Model	OV-90 CDX model
In Vitro Model	Ovarian adenocarcinoma	OV-90 cells		CVCL_3768

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 70.60% (Day 95)	Low FOLR1 expression (FOLR1+)
Method Description	SCID mice bearing OV90 subcutaneous ovarian xenografts, which express folate receptor alpha heterogeneously, at a very low level (H-Score 40)16 were treated with ADC 15 (DAR 3.2).as treatment with a single i.v. dose of 0.7 mg/kg.
In Vivo Model	Ovarian cancer PDX model (PDX: OV90)
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.27% (Day 95)	Low FOLR1 expression (FOLR1+)
Method Description	SCID mice bearing OV90 subcutaneous ovarian xenografts, which express folate receptor alpha heterogeneously, at a very low level (H-Score 40)16 were treated with ADC 15 (DAR 3.2).as treatment with a single i.v. dose of 1.4 mg/kg.
In Vivo Model	Ovarian cancer PDX model (PDX: OV90)
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 35)	Low FOLR1 expression (FOLR1+)
Method Description	SCID mice bearing OV90 subcutaneous ovarian xenografts, which express folate receptor alpha heterogeneously, at a very low level (H-Score 40)16 were treated with ADC 15 (DAR 3.2).as treatment with a single i.v. dose of 0.7 mg/kg.
In Vivo Model	Ovarian cancer PDX model (PDX: OV90)
Experiment 4 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 35)	Low FOLR1 expression (FOLR1+)
Method Description	SCID mice bearing OV90 subcutaneous ovarian xenografts, which express folate receptor alpha heterogeneously, at a very low level (H-Score 40)16 were treated with ADC 15 (DAR 3.2).as treatment with a single i.v. dose of 1.4 mg/kg.
In Vivo Model	Ovarian cancer PDX model (PDX: OV90)
Experiment 5 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 35)	Low FOLR1 expression (FOLR1+)
Method Description	SCID mice bearing OV90 subcutaneous ovarian xenografts, which express folate receptor alpha heterogeneously, at a very low level (H-Score 40)16 were treated with ADC 15 (DAR 3.2).as treatment with a single i.v. dose of 2.7 mg/kg.
In Vivo Model	Ovarian cancer PDX model (PDX: OV90)
Experiment 6 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 95)	Low FOLR1 expression (FOLR1+)
Method Description	SCID mice bearing OV90 subcutaneous ovarian xenografts, which express folate receptor alpha heterogeneously, at a very low level (H-Score 40)16 were treated with ADC 15 (DAR 3.2).as treatment with a single i.v. dose of 2.7 mg/kg.
In Vivo Model	Ovarian cancer PDX model (PDX: OV90)

Experiment 1 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 35)	Positive FOLR1 expression (FOLR1+++/++)
Method Description	Animals with established tumors were randomized into six mice per treatment group and dosed with a single i.v. dose of vehicle or IGN ADCs at either 3 ug/kg drug dose.
In Vivo Model	NCI-H2110 CDX model
In Vitro Model	Lung non-small cell carcinoma	NCI-H2110 cells		CVCL_1530

Experiment 1 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.00 pM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 2 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Effective Concentration (EC50)	9.30 pM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 3 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Effective Concentration (EC50)	30.00 pM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553
Experiment 4 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Effective Concentration (EC50)	30.00 pM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
In Vitro Model	Ovarian adenocarcinoma	OV-90 cells		CVCL_3768
Experiment 5 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.20 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
In Vitro Model	Lung non-small cell carcinoma	NCI-H2110 cells		CVCL_1530

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10.00 pM	Positive FOLR1 expression (FOLR1+++/++)
Method Description	Conjugates or free drug compounds were diluted in RPMI-1640 supplemented with heat-inactivated 10% FBS and 0.1 mg/ml gentamycin , and added to the plated cells. To determine specificity of cytotoxic activity of the conjugates an excess of unconjugated antibody was added to a separate set of diluted conjugates.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10 nM	Negative FOLR1 expression (FOLR1-)
Method Description	Conjugates or free drug compounds were diluted in RPMI-1640 supplemented with heat-inactivated 10% FBS and 0.1 mg/ml gentamycin , and added to the plated cells. To determine specificity of cytotoxic activity of the conjugates an excess of unconjugated antibody was added to a separate set of diluted conjugates.
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20.00 pM	Positive FOLR1 expression (FOLR1+++/++)
Method Description	Conjugates or free drug compounds were diluted in RPMI-1640 supplemented with heat-inactivated 10% FBS and 0.1 mg/ml gentamycin , and added to the plated cells. To determine specificity of cytotoxic activity of the conjugates an excess of unconjugated antibody was added to a separate set of diluted conjugates.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.30 nM	Negative FOLR1 expression (FOLR1-)
Method Description	Conjugates or free drug compounds were diluted in RPMI-1640 supplemented with heat-inactivated 10% FBS and 0.1 mg/ml gentamycin , and added to the plated cells. To determine specificity of cytotoxic activity of the conjugates an excess of unconjugated antibody was added to a separate set of diluted conjugates.
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10 nM	Positive FOLR1 expression (FOLR1+++/++)
Method Description	Conjugates or free drug compounds were diluted in RPMI-1640 supplemented with heat-inactivated 10% FBS and 0.1 mg/ml gentamycin , and added to the plated cells. To determine specificity of cytotoxic activity of the conjugates an excess of unconjugated antibody was added to a separate set of diluted conjugates.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 3.00 nM	Negative FOLR1 expression (FOLR1-)
Method Description	Conjugates or free drug compounds were diluted in RPMI-1640 supplemented with heat-inactivated 10% FBS and 0.1 mg/ml gentamycin , and added to the plated cells. To determine specificity of cytotoxic activity of the conjugates an excess of unconjugated antibody was added to a separate set of diluted conjugates.
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553

Experiment 1 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.00 pM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 2 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Effective Concentration (EC50)	18.00 pM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 3 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Effective Concentration (EC50)	20.00 pM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553
Experiment 4 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Effective Concentration (EC50)	30.00 pM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
In Vitro Model	Ovarian adenocarcinoma	OV-90 cells		CVCL_3768
Experiment 5 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Effective Concentration (EC50)	50.00 pM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were incubated with a serial dilution of conjugate, and a mixture of conjugate and excess, unconjugated anti-EGFR (0.35 M) or anti-FR antibody (1 M), respectively (blocking). After 4 days of continuous treatment with conjugates, cell viability was determined using Cell Titer Glo reagent.
In Vitro Model	Lung non-small cell carcinoma	NCI-H2110 cells		CVCL_1530

Ref 1	IMGN151-A next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression. Cancer Res (2020) 80 (16_Supplement): 2890.
Ref 2	Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs). ACS Med Chem Lett. 2019 Jul 22;10(8):1211-1215. doi: 10.1021/acsmedchemlett.9b00254. eCollection 2019 Aug 8.
Ref 3	Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers. Mol Pharm. 2019 Dec 2;16(12):4817-4825. doi: 10.1021/acs.molpharmaceut.9b00696. Epub 2019 Oct 29.